Drug Database
AZ

azathioprine (azathioprine, Salix / Azasan / Azasan)

✓ Approved

Salix · 小分子 · 小分子

什么是 azathioprine?

azathioprine 是一种小分子,由Salix研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名azathioprine, Salix, Azasan, Azasan
公司Salix
药物类别小分子
给药途径Oral (PO)
状态Approved

治疗适应症

azathioprine 针对 2 个适应症,涉及 2 个治疗领域。

治疗领域疾病/病症分期
Musculoskeletal and connective tissue disordersRheumatoid arthritis✓ Approved
Immune system disordersSolid organ transplant rejection✓ Approved

相关研究文献

PubMedHepatology international2026-11-18

Clinical characteristics, temporal trends, and predictors of liver transplantation-free survival in patients with autoimmune hepatitis: a nationwide Japanese registry study.

Abe Kazumichi K, Ohira Hiromasa H, Takahashi Atsushi A, Hayashi Manabu M et al.

Complete biochemical response (CBR) is a key therapeutic target in autoimmune hepatitis (AIH), but nationwide Japanese data linking treatment response, temporal changes in practice, and liver transplantation (LT)-free survival remain limited. We evaluated clinical characteristics, diagnostic period trends, and predictors of LT-free survival using the Japanese Autoimmune Hepatitis Study Group registry. Patients newly diagnosed with AIH between 1998 and 2024 were screened. Baseline diagnostic data were available for 3992 patients, and 2494 patients with follow-up data were included in the survival analysis. Landmark analyses were performed at 6 and 12 months after treatment initiation. CBR was defined as the normalization of serum AST, ALT, and IgG levels. LT-free survival was assessed using Kaplan‒Meier analysis and Cox proportional hazards models. Among 3992 patients, 1163 were diagnosed from 2018 onward. Recent patients were older and had a slightly lower female proportion, more frequent cirrhosis at diagnosis, and more frequent azathioprine and ursodeoxycholic acid use. In the survival cohort, the median age was 63 years, 82.6% were female, and 10.8% had cirrhosis. During a median follow-up of 3.2 years, CBR was achieved in 53.5% at the 6-month landmark and 66.9% at the 12-month landmark. The estimated LT-free survival rates were 96.6% at 3 years and 95.8% at 5 years. Older age, male sex, cirrhosis at diagnosis, and a lack of CBR at the 6- or 12-month landmark independently predicted poorer LT-free survival. In liver-specific analyses, cirrhosis at diagnosis and lack of early CBR remained associated with liver-related death or LT. Baseline cirrhosis and failure to achieve early CBR may help identify high-risk AIH patients who require closer monitoring and clinical reassessment.

PMID 43050012
阅读全文 →
PubMedCureus2026-11-18

First Reported Coexistence of Acetylcholine Receptor-Positive Myasthenia Gravis and Genetically Confirmed Spinocerebellar Ataxia Type 6.

Abou Zeid Jawad J, Shin Kedrick K, Sleiman Patrick P, Ahmed Saniya S et al.

When a patient with a long-standing neurological diagnosis develops new symptoms, those symptoms are frequently attributed to the disease that is already known, and a second, unrelated disorder may remain unrecognized for years. We describe a patient in whom myasthenia gravis (MG) and spinocerebellar ataxia type 6 (SCA6) occurred together, a combination that has not, to our knowledge, been previously reported. A 57-year-old man with acetylcholine receptor antibody-positive MG diagnosed in 1983 presented with progressive imbalance despite largely stable MG symptoms. His MG remained well controlled on low-dose prednisone and pyridostigmine following thymectomy, with intermittent azathioprine therapy. Neurological examination demonstrated cerebellar signs including dysmetria, dysdiadochokinesia, gaze-evoked nystagmus, and dysarthria. Brain MRI showed atrophy of the cerebellar hemispheres and vermis with associated brainstem volume loss. Extensive evaluation for acquired causes of cerebellar ataxia/degeneration, including paraneoplastic and autoimmune antibody testing, was unrevealing. Progressive ataxia continued despite largely stable neuromuscular symptoms. Family history revealed ataxia in his father and a similar disorder in his identical twin brother. Several years before the diagnosis was established, he experienced an MG exacerbation with bulbar and generalized weakness that responded to plasmapheresis. Genetic testing subsequently identified a pathogenic CACNA1A CAG repeat expansion of 22 repeats, confirming SCA6, just over a decade after the initial onset of his ataxia symptoms and establishing the coexistence of two distinct and rare neurological disorders. This case highlights the diagnostic challenge of evaluating new neurological symptoms in patients with established chronic, rare neurological disease. Progressive cerebellar dysfunction was initially overshadowed by the patient's longstanding MG, resulting in delayed recognition of a hereditary ataxia. Clinicians should maintain a broad differential diagnosis when symptoms evolve in a manner that is atypical for the known disease process. Recognition of coexisting neurological disorders is essential for accurate diagnosis, prognostication, genetic counseling, and multidisciplinary management. Coexistence of an acquired neuromuscular disorder and a hereditary cerebellar ataxia is possible; antibody testing to exclude an acquired ataxia and genetic confirmation of the inherited disorder are both required, and recognition of both diagnoses directly informs immunotherapy decisions, rehabilitation, and family counselling.

PMID 43047322
阅读全文 →
PubMedTherapeutic advances in neurological disorders2026-11-18

A multicentre study on predictors of relapses in AQP4-IgG NMOSD: Do titres matter?

Zhan Jiayang J, Ge Huizhen H, Hu Jinquan J, Luo Lijun L et al.

Neuromyelitis Optica Spectrum Disorder (NMOSD) is a severe autoimmune-mediated inflammatory condition affecting the central nervous system. While various factors, such as immunotherapy regimens, influence the risk of relapse, the predictive significance of aquaporin-4 immunoglobulin G (AQP4-IgG) status is still debated. Identifying the determinants of disease severity and factors associated with relapse is essential for the development of personalized therapeutic strategies. This study aims to identify risk factors associated with relapse in patients diagnosed with serum AQP4 antibody-positive NMOSD. Additionally, it seeks to examine the impact of various traditional immunotherapy regimens and the different titres of AQP4-IgG on the relapse rates in these patients. This retrospective cohort study, conducted across multiple centers, examined longitudinal data from 314 seropositive AQP4-IgG NMOSD patients treated at seven medical centers from January 2014 to June 2024. This study used annualized relapse rate (ARR) as the outcome measure. Kaplan-Meier, logistic regression, and Cox regression were used to assess the risk factors for relapse. The specific titers of AQP4-IgG were classified into different subgroups: negative, low-positive, moderate-positive, and high-positive. The relapse rate was compared among different AQP4-IgG titers and treatment patterns (tacrolimus, mycophenolate mofetil, azathioprine, oral glucocorticoid-only, or no medication). We reviewed 314 AQP4-IgG positive (median [IQR] age at onset: 45.0 [33.0, 54.0] years; 86.0% female) NMOSD inpatients and outpatients. The median disease duration was 47 (26, 84) months. The median relapse-free survival period for patients with NMOSD was 30 months. AQP4-IgG seropositive status (OR =6.75,95% CI 2.95-15.46,P<0.001)during the disease course and multisystem involvement at initial onset (OR =1.89,95% CI 1.025-3.486,P = 0.041) were identified as independent risk factors for relapse. Patients who received standardized immunotherapy during remission (OR = 0.05,95% CI 0.02-0.14,P<0.001) demonstrated a significantly reduced risk of relapse. In contrast, the median relapse time for patients treated solely with oral glucocorticoids was comparable to that of untreated controls (HR=0.92, 95% CI 0.68-1.23, P=0.561). Patients who achieved seronegative status during observation exhibited the longest median interval between relapses. Seroconversion to AQP4-IgG negativity (HR=0.40,95%CI 0.21-0.75,P=0.005) during observation was associated with a reduction in both relapse frequency and annualized relapse rate (ARR). The implementation of standardized immunotherapy markedly decreased the incidence of relapse in patients with NMOSD. Multisystem involvement at initial onset and AQP4-IgG seropositive status during the course of the disease were predictive of a higher likelihood of relapse.

PMID 43047906
阅读全文 →
PubMedJournal of pediatric gastroenterology and nutrition2026-11-17

Treatment of pediatric autoimmune liver disease beyond prednisolone and azathioprine in a cohort of 115 patients.

Korell Marie M, Kramer Miriam M, Poets Alina A, Mutschler Frauke F et al.

Pediatric autoimmune hepatitis (pAIH) is an acute or chronic inflammatory liver disease, caused by a dysregulation of the immune system. Autoimmune sclerosing cholangitis (ASC) additionally affects the bile ducts. Traditional first-line treatment (FLT) consists of prednisolone and azathioprine. If pAIH/ASC remains untreated or biochemical remission (BR) is not achieved, end-stage liver disease develops. We aimed to analyze the 6-months-outcomes of various second- and third-line therapies for pAIH/ASC. This is a retrospective single-center analysis, including all cases of patients with pAIH or ASC between 2000 and 2025. All patients were diagnosed based on published European Society for Paediatric Gastroenterology, Hepatology and Nutrition diagnostic criteria. Of 115 patients with pAIH or ASC, 26 patients required an alternative therapy (altT) other than prednisolone and azathioprine, most of them due to non-BR, including due to non-compliance. The 6-month outcome shows, that tumor necrosis factor (TNF)-alpha inhibitors overall achieved the best results with a BR rate of 40% (n = 2/5). This was closely followed by cyclosporin A (CSA), with a BR rate of 36.4% (n = 4/11), which was the most commonly used drug in our study. Patients with inflammatory bowel disease are significantly more likely to need altT. The overall BR rate 6 months after start of altT is low and decreases with each stage of therapy, the TNF-alpha inhibitors demonstrated the highest BR rate for altT. Non-compliance is a significant problem in general, so it is unclear whether the success of this therapy is solely attributable to the drug's inherent immunomodulatory function or to its controlled administration via intravenous injection. The prospective evaluation of this novel, low-side-effect management option warrants further explorations.

PMID 43042670
阅读全文 →
PubMedJournal of medical cases2026-11-17

A Rare Post-Hair Transplant Complication With Complete Recovery.

Tcholadze Ekaterine E, Javakhadze Malvina M, Goliadze Lia L, Kanashvili Marine M et al.

Postoperative complications following hair transplantation are generally mild and self-limited; however, severe infectious or inflammatory reactions involving the periorbital or cervicofacial regions are exceedingly rare yet potentially vision- or life-threatening. Early recognition and prompt multidisciplinary management are essential, as delayed intervention may result in rapid soft-tissue progression, necrosis, and systemic instability. A 34-year-old man developed rapidly progressive cervicofacial edema 48 h after an uncomplicated hair transplantation procedure. The patient had no history of prior cranial surgery, trauma, or implanted prosthetic material. The swelling originated in the recipient area and rapidly extended to the forehead and bilateral periorbital regions, accompanied by severe pain, fever, hypotension, and hemodynamic instability. Laboratory evaluation demonstrated markedly elevated inflammatory markers (C-reactive protein 193 mg/L (reference < 5 mg/L), procalcitonin 51.43 ng/mL (reference < 0.05 ng/mL), lactate 9.68 mmol/L (reference 0.5-2.2 mmol/L)) with progressive leukopenia. Despite empirical broad-spectrum antibiotics, intensive care support, and multidisciplinary management, the patient's condition deteriorated, with worsening edema, hemorrhagic-purulent bullae, bilateral pleural effusions, and atrial fibrillation with rapid ventricular response. Subsequent periorbital skin necrosis required surgical debridement. Later during hospitalization, neck soft-tissue involvement with multiple small fluid collections emerged. Gradual improvement followed escalation of antimicrobial therapy and corticosteroid administration; however, residual frontal muscle akinesia and right facial nerve paresis persisted. The patient eventually stabilized on long-term azathioprine therapy and achieved full clinical recovery. This case underscores that rapidly progressive cervicofacial edema, periorbital involvement, frontal muscle akinesia, and right facial nerve paresis after hair transplantation, although rare, may indicate a fulminant infectious or inflammatory process requiring urgent, multidisciplinary management. Early recognition, timely therapeutic escalation, and close monitoring are critical to preventing irreversible tissue damage and systemic complications. Increased awareness of such severe postoperative reactions can enhance clinical vigilance and improve patient outcomes.

PMID 43042419
阅读全文 →
PubMedAmerican journal of kidney diseases : the official journal of the National Kidney Foundation2026-11-17

Relapse of ANCA-Associated Vasculitis With Kidney Involvement: A Cohort Study.

Milon Victor V, Samoreau Clément C, Desouche Alice A, Fage Nicolas N et al.

Relapses remain clinically important in ANCA-associated vasculitis with kidney involvement (AAV-KI). This study sought to characterize their patterns of occurrence, the factors associated with relapse, and the association of relapse with kidney outcomes. Retrospective multicenter cohort study. Adults with AAV-KI diagnosed between 2000 and 2025 in 7 French centers. A total of 460 patients were included. For the outcome of relapse, baseline clinical, biological, histological, and therapeutic variables, previously published relapse-risk scores, and biomarkers measured at 6, 12, and 24 months. For the outcomes of kidney failure and death, major relapse was modeled as a time-dependent exposure. First major relapse, relapse-event characteristics, kidney failure, and death. Cumulative incidence of relapse was estimated using competing-risk methods with death as a competing event. Cause-specific Cox models identified factors associated with the first major relapse. Landmark analyses assessed post-diagnosis factors associated with relapse. Relapse was modeled as a time-dependent exposure for the outcomes of kidney failure and death. Model discrimination was assessed using the C-index. Over a median follow-up of 62 months, 107 patients (23%) experienced 135 major relapses. The 10-year cumulative incidence of relapse was 31%, and the overall relapse rate was 48.6 per 1,000 patient-years. Relapses involved the kidney in 83 events (61%) and involved, at times, organs not affected at diagnosis. Relapse was associated with a higher risk of kidney failure (adjusted HR, 4.03; 95% CI, 2.03-8.00), but not with death. Higher eGFR at diagnosis, granulomatosis with polyangiitis (GPA) phenotype, ANCA positivity during follow-up, azathioprine maintenance, and kidney biopsy findings were associated with relapse, but their ability to discriminate between those who did and did not experience relapse was modest Existing relapse scores showed poor discrimination (C-index ≤0.56), and the best multivariable landmark model having a C-index of 0.71. Retrospective design, evolving treatment practices, residual confounding, and missing follow-up biomarker data. In AAV-KI, relapses are phenotype-dependent, frequently involve the kidney, and are strongly associated with subsequent kidney failure. Despite this, the ability to discriminate between patients who do and do not experience relapses remains insufficient. These findings suggest a potential role for dynamic risk models that incorporate longitudinal biomarkers and kidney measures.

PMID 43044903
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多azathioprine